The pyrogen testing market size in Europe is expected to be worth USD 334 million by 2028 from USD 186.22 million in 2023, growing at a CAGR of 12.4% from 2023 to 2028.
Increasing demand for pyrogenic testing products in the pharmaceutical and biotechnology sectors, such as Pfizer, Inc., Merck Group, and others, as well as medical devices and government support for these industries and government support for these industries, is projected to boost the pyrogen testing market in the European region over the forecast period. Also, the increasing number of market participants in Europe and mergers and acquisitions are likely to drive market expansion.
The European market for pyrogen testing products is further predicted to rise in response to fast-developing pharmaceutical and biotechnology manufacturing and an increasing number of new therapies promotions. On the other hand, the growing investments in research and development are another essential aspect contributing to market expansion. Therefore, manufacturers use new product development and launch as a vital strategy to maintain their dominance and increase their revenue share in the division.
In addition, the growing number of biological products, government assistance, and the introduction of new drugs are also propelling the market forward. Furthermore, the rising prevalence of chronic diseases and a growing focus on research and development are two major factors driving the market expansion. Furthermore, the increased need for rehabilitative treatments for life-threatening conditions such as cancer and diabetes underscore the importance of drug development and research. As a result, the market for pyrogen testing kits is predicted to rise rapidly due to the requirement for better quality monitoring and regulation.
The primary barriers to the European pyrogen testing market expansion include unfavorable regulatory rules and reimbursement problems. To a small extent, strict government regulatory frameworks for drugs and a lengthy approval process for the drugs market are projected to impede market growth.
This research report on the European pyrogen testing market has been segmented and sub-segmented into the following categories:
By Test Type:
Geographically, the European regional market is the second-largest market for pyrogen testing globally, accounting for a market share of 24%. The regional market growth is growing owing to the availability of advanced healthcare infrastructure and favorable reimbursement policies. The UK pyrogen testing market dominated the European market in 2020. On the other hand, the German pyrogen testing market is expected to expand at the fastest rate due to the rising incidence of chronic disorders. With the largest market share, the United Kingdom leads the European pyrogen testing market. Increased government backing for the pharmaceutical and biotechnology industries adds fuel to the pyrogen testing market’s growth. In addition, the market would be boosted by continual research and development to advance new pharmaceuticals.
The pyrogen testing market in Germany is predicted to grow rapidly in this region. The massive investments made by the government and various commercial companies in research and development and favorable government suggestions made by Germany are propelling the pyrogen testing market forward.
Other countries, such as France, Spain, and Italy, are expected to rise significantly in the coming years. Furthermore, a rapidly growing healthcare infrastructure, a massive genome pool, and the availability of strict minimum guidelines for developing novel drugs and an increase in chronic diseases boost the production of biologics, medical devices, and pharmaceuticals, promoting the market even more.
KEY MARKET PLAYERS:
A few of the notable companies operating in the Europe pyrogen testing market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck Kgaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc., and WUXI Pharmatech (Cayman) Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org